Edition:
United Kingdom

GlaxoSmithKline Pharmaceuticals Ltd (GLAX.NS)

GLAX.NS on National Stock Exchange of India

1,290.30INR
11:13am BST
Change (% chg)

Rs-4.65 (-0.36%)
Prev Close
Rs1,294.95
Open
Rs1,294.95
Day's High
Rs1,295.00
Day's Low
Rs1,284.90
Volume
5,502
Avg. Vol
15,169
52-wk High
Rs1,800.05
52-wk Low
Rs1,153.97

Latest Key Developments (Source: Significant Developments)

India's Glaxosmithkline Pharmaceuticals Gets Shareholders' Nod For Issue Of Bonus Shares
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd ::GETS SHAREHOLDERS' NOD FOR THE ISSUE OF BONUS SHARES.  Full Article

Glaxosmithkline Pharmaceuticals ‍appoints Puja Thakur as CFO​
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Glaxosmithkline Pharmaceuticals Ltd ::Says ‍appointed Puja Thakur as whole-time director and CFO​.  Full Article

India's Glaxosmithkline Pharmaceuticals Sept-qtr profit up 32 pct
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Glaxosmithkline Pharmaceuticals Ltd ::Sept quarter profit 1.30 billion rupees versus profit of 988.5 million rupees last year.Sept quarter revenue from operations 8.36 billion rupees versus 7.99 billion rupees last year.  Full Article

India's Glaxosmithkline Pharmaceuticals June-qtr profit down about 63 pct
Tuesday, 25 Jul 2017 

July 25 (Reuters) - Glaxosmithkline Pharmaceuticals Ltd :June quarter profit 264.2 million rupees versus profit of 722.7 million rupees last year.June quarter total revenue from operations 6.07 billion rupees versus 7.05 billion rupees last year.  Full Article

India's Glaxosmithkline Pharma March-qtr profit rises about 6 pct
Friday, 19 May 2017 

May 19 (Reuters) - Glaxosmithkline Pharmaceuticals Ltd :March quarter net profit 1.13 billion rupees.Says recommended a dividend of 300 pct on equity share capital.March quarter total income from operations 7.84 billion rupees.Net profit in March quarter last year was 1.06 billion rupees as per IND-AS; total income from operations was 7.06 billion rupees.Says re-appointed Andrew Aristidou as CFO.  Full Article

FDA approves Mylan's generic of Advair asthma treatment

Jan 30 The U.S. Food and Drug Administration (FDA) approved Mylan NV's generic version of GlaxoSmithKline-developed blockbuster asthma treatment Advair, driving shares of Mylan 7 percent higher on Wednesday.